The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?

The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?

Waldenström Macroglobulinemia (WM) is a rare, indolent B-cell lymphoma that primarily affects elderly individuals. Although frontline chemoimmunotherapy and Bruton’s tyrosine kinase inhibitors (BTKi) can provide durable responses, most patients eventually relapse, posing ongoing clinical challenges....

Full description

Saved in:
Bibliographic Details
Main Authors: Nicolò Danesin, Giovanni Leone, Mattia D’Antiga, Marco Carraro, Greta Scapinello, Livio Trentin, Francesco Piazza
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Hematology
Subjects:
Waldenstöm’s Macroglobulinemia
lymphoplasmacytic cells
non-Hodgkin lymphoma (NHL)
BTK inhibition
B-cell lymphoma 2 inhibition (BCL2)
target therapies
Online Access:https://www.frontiersin.org/articles/10.3389/frhem.2025.1624046/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/frhem.2025.1624046/full

Similar Items